CN111574610A - 大黄鱼抗菌肽piscidin 5-like type 4及其制备方法与应用 - Google Patents

大黄鱼抗菌肽piscidin 5-like type 4及其制备方法与应用 Download PDF

Info

Publication number
CN111574610A
CN111574610A CN202010512768.2A CN202010512768A CN111574610A CN 111574610 A CN111574610 A CN 111574610A CN 202010512768 A CN202010512768 A CN 202010512768A CN 111574610 A CN111574610 A CN 111574610A
Authority
CN
China
Prior art keywords
type4
piscidin
recombinant
rlc
large yellow
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202010512768.2A
Other languages
English (en)
Other versions
CN111574610B (zh
Inventor
郑利兵
迟长凤
邱佳寅
潘滢
陈佳
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ningbo Fufa Aquatic Products Co ltd
Original Assignee
Ningbo Fufa Aquatic Products Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ningbo Fufa Aquatic Products Co ltd filed Critical Ningbo Fufa Aquatic Products Co ltd
Priority to CN202010512768.2A priority Critical patent/CN111574610B/zh
Publication of CN111574610A publication Critical patent/CN111574610A/zh
Application granted granted Critical
Publication of CN111574610B publication Critical patent/CN111574610B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/461Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from fish
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23KFODDER
    • A23K20/00Accessory food factors for animal feeding-stuffs
    • A23K20/10Organic substances
    • A23K20/142Amino acids; Derivatives thereof
    • A23K20/147Polymeric derivatives, e.g. peptides or proteins
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23KFODDER
    • A23K50/00Feeding-stuffs specially adapted for particular animals
    • A23K50/80Feeding-stuffs specially adapted for particular animals for aquatic animals, e.g. fish, crustaceans or molluscs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/02Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/14Ectoparasiticides, e.g. scabicides
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70Vectors or expression systems specially adapted for E. coli
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A40/00Adaptation technologies in agriculture, forestry, livestock or agroalimentary production
    • Y02A40/80Adaptation technologies in agriculture, forestry, livestock or agroalimentary production in fisheries management
    • Y02A40/81Aquaculture, e.g. of fish

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Polymers & Plastics (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Food Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Animal Husbandry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Insects & Arthropods (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Birds (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)

Abstract

大黄鱼抗菌肽piscidin 5‑like type 4及其制备方法与应用,涉及大黄鱼抗菌肽。大黄鱼抗菌肽piscidin 5 like type 4命名为Lc‑P5L4。构建Lc‑P5L4重组表达载体;将所得的重组表达载体转化宿主细胞,并对宿主细胞进行诱导表达,获得表达产物;分离纯化所得的表达产物,获得重组蛋白,即rLc‑P5L4。所述rLc‑P5L4对刺激隐核虫幼虫、滋养体具有明显的抑杀活性,因此所述大黄鱼抗菌肽piscidin 5‑like type 4在制备抗虫药物和作为水产养殖业中防治病害的饲料添加剂中具有广泛的应用价值。

Description

大黄鱼抗菌肽piscidin 5-like type 4及其制备方法与应用
技术领域
本发明涉及大黄鱼抗菌肽,尤其是涉及一种大黄鱼抗菌肽piscidin 5-like type4及其制备方法与应用。
背景技术
大黄鱼产业是我国最大的海鱼产业之一。2000年以来,大黄鱼产量占海鱼总产量的比例一直保持稳定增长的趋势([1]Qiao Y..Sequencing and correlation analysisof miRNAand transcriptome of Larimichthys crocea infencted by Cryptocaryonirritans[D].Xiamen:Xiamen University.2016)。然而由于养殖环境的无序发展和严重污染导致了各种疾病的爆发。特别是由刺激隐核虫引起的海洋白斑病。自2005年以来,每年都可能导致大量大型黄花鱼死亡,造成巨大的经济损失([2]Liu Z.Y.,Xie Y.Q.,Lin X.J.,Fan X.J.,2014.Research on the Cryptocaryoniosis of marine fishes from theperspective of epidemiology in Ningde of Fujian[J].Journal of FujianFisheries.36(5),351-358;[3]Niu S.F..Study on the antiparasiticcharacterization of piscidin-like in two sciaenoid fishes[D];Xiamen:Xiamenuniversity,2013)。目前,海洋白斑病的主要防治方法是化学药物,但是化学药物不仅影响有限,而且会带来更严重的问题,如海水污染和药物残留。因此,海洋白斑病已成为大黄鱼乃至整个海洋硬骨鱼养殖业疾病防治的重大技术难题。
抗菌肽(AMPs)作为天然免疫系统中的活性成分,其抗寄生虫活性引起关注。Piscidins是AMPs家族的中一员,是硬骨鱼类特有的一类AMPs,最早是从杂交斑纹鲈(Morone chrysops×M.saxatilis)的肥大细胞中分离得到([4]Silphaduang U.,NogaE.J..2001.Antimicrobials-Peptide antibiotics in mast cells of fish[J].Nature.414(6861),268-269)。杂交斑纹鲈Piscidins2在体外具有抗寄生虫活性,可引起刺激隐核虫幼虫肿胀、死亡、解体;小瓜虫(Ichthyophthirius multifiliis)对Piscidins2更敏感,可能是由于影响其活性的阳离子浓度不同([5]Colorni A.,Ullal A.,HeinischG.,Noga E.J.,2008.Activity of the antimicrobial polypeptide piscidin 2againstfish ectoparasites[J].J Fish Dis.31(6),423-432)。白鲈鱼Piscidins 6无抑菌活性,但可引起收缩性囊泡肿胀、表面膜破坏、细胞膜空泡化;其对淡水纤毛虫的毒性强于海洋纤毛虫([6]Salger S.A.,Cassady K.R.,Reading B.J.,Noga E.J.,2016.A Diverse Familyof Host-Defense Peptides(Piscidins)Exhibit Specialized Anti-Bacterial andAnti-Protozoal Activities in Fishes[J].PLOS one.11(8),1-25)。杂交斑纹鲈piscidin 7也不具有任何抗菌活性,但它对海洋纤毛虫的活性高于piscidin 6。因此,某些piscidins有独特的抗寄生虫活性。
大黄鱼(Larimichthys crocea)的piscidins-like基因(Lc-pis)不仅可以抑制或杀死一些细菌,特别是一些水生致病菌,而且它也是一个抗虫肽(APP),可以溶解细胞膜,导致滋养体内容物泄漏。随后,从刺激隐核虫免疫的大黄鱼的肝脏比较转录组中发现了piscidin 5-like(Lc-P5L)和piscidin 5-like type 4,表明它们参与了刺激隐核虫感染的防御([7]Zheng L.B.,Mao Y.,Wang J.,Chen R.N.,Su Y.Q.,Hong Y.Q.,Hong Y.J.,Hong Y.C.,2018.Excavating differentially expressed antimicrobial peptidesfrom transcriptome of Larimichthys crocea liver in response to Cryptocaryonirritans[J].Fish&Shellfish Immunology.75,109-114)。Lc-P5L之前已经被克隆并进行了表征([8]Zhou Q.J.,Su Y.Q.,Niu S.F.,Liu M.,Qiao Y.,Wang J.,2014.Discoveryand molecular cloning of piscidin-5-like gene from the large yellow croaker(Larimichthys crocea)[J].Fish&Shellfish Immunology.41,417-420)。体外实验发现,Lc-P5L可引起刺激隐核虫滋养体的核肿胀、细胞膜破裂和内容物渗漏([9]Zheng L.B.,Hong Y.Q.,Sun K.H.,Wang J.,Hong Y.J.,2020.Characteristics delineation ofpiscidin 5like from Larimichthys crocea with evidence for the potentantiparasitic activity[J].Developmental&Comparaive Immunology.Underview)。因此,推测piscidins在对抗刺激隐核虫的过程中可能起着多种关键作用。
体外重组表达抗菌肽piscidin 5-like type 4不仅在研究大黄鱼免疫防御机制方面具有重要意义,而且为研发抗刺激隐核虫药物提供参考依据。
发明内容
本发明的第一目的在于提供大黄鱼抗菌肽piscidin 5-like type 4基因的编码序列。
本发明的第二目的在于提供大黄鱼抗菌肽piscidin 5-like type 4的氨基酸序列。
本发明的第三目的在于提供大黄鱼抗菌肽piscidin 5-like type 4的制备方法。
本发明的第四目的在于提供大黄鱼抗菌肽piscidin 5-like type 4的应用。
所述大黄鱼抗菌肽piscidin 5like type 4命名为Lc-P5L4。
所述Lc-P5L4基因的编码序列为:
Figure BDA0002528897760000021
所述Lc-P5L4的氨基酸序列为:
Figure BDA0002528897760000031
重组piscidin 5-like type 4(rLc-P5L4)的制备方法包括以下步骤:
1)构建Lc-P5L4重组表达载体;
2)将步骤1)所得的重组表达载体转化宿主细胞,并对宿主细胞进行诱导表达,获得表达产物;
3)分离纯化步骤2)所得的表达产物,获得重组蛋白,即rLc-P5L4。
在步骤1)中,所述表达载体可选用pET-32a。
在步骤2)中,所述宿主细胞可选用E.coli BL21(DE3)。
在步骤3)中,可先将步骤2)所得的表达产物进行透析,再进行亲和层析。
所述rLc-P5L4对刺激隐核虫幼虫、滋养体具有明显的抑杀活性,因此所述大黄鱼抗菌肽piscidin 5-like type 4在制备抗虫药物和作为水产养殖业中防治病害的饲料添加剂中具有广泛的应用价值。
本发明在分离得到Lc-P5L4的基础上,根据Lc-P5L4基因序列特征成功构建重组表达载体并在大肠杆菌系统中表达并纯化获得重组rLc-P5L4蛋白,该重组蛋白具有一定的抗菌活性和较强的抗刺激隐核虫活性。研究结果表明,Lc-P5L4是一种重要的先天免疫因子,广泛参与了大黄鱼的抗病原生物感染反应,因此,重组基因工程产品rLc-P5L4在抗虫新药的开发中具有非常诱人的应用前景。
附图说明
图1为pET-32a原核表达载体构建图。
图2为SDS-PAGE分析pET-32a-Lc-P5L4重组大肠杆菌IPTG诱导表达菌体超生破碎后分离上清与沉淀的电泳图,在图2中,M为SDS-PAGE标准蛋白质Marker,1:IPTG诱导前含重组质粒的E.coli BL21(DE3)总细胞提取物,2为IPTG诱导的重组蛋白,3为菌体超生破碎后沉淀,4为超声波处理后的上清液。
图3为纯化产物的western blot图。在图3中,M为SDS-PAGE标准蛋白质Marker。
图4为40μM rLc-P5L4与刺激隐核虫幼虫共孵不同时间的光镜图。在图4中,A为未经处理的空白对照或经rTRX-His-tag处理的阴性对照。B~F为分别用rLc-P5L4处理15min(B)、30min(C)、45min(D)、1.5h(E)、2h(F)。
图5为40μM rLc-P5L4与刺激隐核虫幼虫共孵不同时间的扫描电镜图。在图5中,标尺为10μm,A为未经处理的空白对照或经rTRX-His-tag处理的阴性对照。B~F为分别用rLc-P5L4处理15min(B)、30min(C)、45min(D)、1.5h(E)、2h(F)。
具体实施方式
以下通过实施例结合附图详细说明本发明的技术方案。
实施例1大黄鱼Lc-P5L4原核重组表达载体的构建
根据pET-32a载体多克隆位点,设计带有限制性内切酶位点的特异性引物BNP54-F/R扩增编码大黄鱼piscidin 5-like type 4基因ORF(不含信号肽)。BNP54-F的5′端添加EcoR I酶切位点;BNP54-R的5′端添加Hind III酶切位点。
BNP54-F:5′-CCGGAATTCCAAATTGTCTACGG-3′;
BNP54-R:5′-CCCAAGCTTTTTGCTGCCGTCGT-3′。
扩增Lc-P5L4的编码区片段。PCR反应条件为:94℃预变性5min;94℃变性45s,58℃退火45s,72℃延伸45s,重复35个循环;72℃延伸10min。
利用琼脂糖凝胶纯化试剂盒回收PCR产物,回收的PCR产物经EcoR I和Hind III酶切后纯化回收,与EcoR I和Hind III双酶切线性化的pET-32a载体连接,构建好大肠杆菌表达重组载体pET-32a-Lc-P5L4,测序鉴定读码框准确无误。
pET-32a-Lc-P5L4载体构建图参见图1。
实施例2 pET-32a-Lc-P5L4重组质粒在E.coli BL21(DE3)中的诱导表达
测序正确的质粒pET-32a-Lc-P5L4经热激法转化至E.coli BL21(DE3)大肠杆菌中,并用IPTG诱导表达。
结果显示,与诱导前相比,pET-32a-Lc-P5L4重组质粒转化的E.coli BL21(DE3)有明显的重组蛋白的诱导表达,蛋白条带在25KDa左右(参见图2和3)。
实施例3 pET-32a-Lc-P5L4重组质粒转化的E.coli BL21(DE3)中IPTG诱导后的表达产物纯化
利用亲和层析法纯化rLc-P5L4重组蛋白,大量诱导表达的阳性重组E.coli BL21(DE3)后,上层清液被离心法收获,通过0.22μm过滤器过滤后,上清液通过HisCap 6FF柱,对rLc-P5L4进行亲和吸附,该柱经过无菌MilliQ水和Tris-HCl缓冲液(50mM Tris-HCl,500mMNaCl,20mM咪唑,pH 7.8)预处理。然后用AKTA净化器100梯度咪唑清洗柱洗脱。收集洗脱组分,经SDS-PAGE电泳分析,可见约25KDa的单一条带(参见图2和3)。
实施例4纯化产物的western blot分析
经western blot分析,所获取的纯化产物为大黄鱼piscidin 5-like type 4蛋白。
实施例5rLc-P5L4的抗刺激隐核虫幼虫、滋养体活性鉴定
rLc-HepL的抗刺激隐核虫活性鉴定:将目的蛋白浓缩后,与从包囊孵化后4h之内的刺激隐核虫幼虫室温共孵2h,并在不同时间取样进行5%戊二醛固定,在倒置显微镜下观察幼虫的形态变化。空白对照组为未作任何处理的幼虫,阴性对照组为40μM rTRX-His-tag共孵幼虫,实验组为40μM rLc-P5L4与幼虫共孵。结果显示,相比于空白对照组和阴性对照组,实验组中刺激隐核虫幼虫逐渐出现体纤毛不可见,一些不知名絮状物包裹虫体周围,造成虫体聚集现象,继而整个虫体变形,并在某个虫体某个部位发生细胞膜破裂、内容物外泄,最后虫体分解。因此说明rLc-P5L4具有一定的抗刺激隐核虫活性。
图4给出40μM rLc-P5L4与刺激隐核虫幼虫共孵不同时间的光镜图。图5给出40μMrLc-P5L4与刺激隐核虫幼虫共孵不同时间的扫描电镜图。
本发明根据大黄鱼抗虫肽piscidin 5-like type 4基因序列特征,构建原核表达载体、转化大肠杆菌IPTG诱导表达并纯化获得rLc-P5L4重组蛋白,从而鉴定重组蛋白抗刺激隐核虫的活性。
序列表
<110> 宁德市富发水产有限公司
<120> 大黄鱼抗菌肽piscidin 5-like type 4及其制备方法与应用
<160> 2
<170> SIPOSequenceListing 1.0
<210> 1
<211> 198
<212> DNA
<213> 大黄鱼(Larimichthys crocea)
<400> 1
atgaagggtg ttatgatctt tctggtgttg acgctggtcg tcctcatggc cggggagagt 60
cttggacaaa ttgtctacgg tcacaacact catgtggggg gcagcgtcgg cgacatcggc 120
ggcagcttca atggtgtgag gtatcggtct cgctggcagc ggtccctgcc agggtcggag 180
gacgacggca gcaaatag 198
<210> 2
<211> 65
<212> PRT
<213> 大黄鱼(Larimichthys crocea)
<400> 2
Met Lys Gly Val Met Ile Phe Leu Val Leu Thr Leu Val Val Leu Met
1 5 10 15
Ala Gly Glu Ser Leu Gly Gln Ile Val Tyr Gly His Asn Thr His Val
20 25 30
Gly Gly Ser Val Gly Asp Ile Gly Gly Ser Phe Asn Gly Val Arg Tyr
35 40 45
Arg Ser Arg Trp Gln Arg Ser Leu Pro Gly Ser Glu Asp Asp Gly Ser
50 55 60
Lys
65

Claims (8)

1.Lc-P5L4基因的编码序列为:
Figure FDA0002528897750000011
2.Lc-P5L4的氨基酸序列为:
Figure FDA0002528897750000012
3.重组piscidin 5-like type 4的制备方法,其特征在于包括以下步骤:
1)构建Lc-P5L4重组表达载体;
2)将步骤1)所得的重组表达载体转化宿主细胞,并对宿主细胞进行诱导表达,获得表达产物;
3)分离纯化步骤2)所得的表达产物,获得重组蛋白,即rLc-P5L4。
4.如权利要求3所述重组piscidin 5-like type 4的制备方法,其特征在于在步骤1)中,所述表达载体选用pET-32a。
5.如权利要求3所述重组piscidin 5-like type 4的制备方法,其特征在于在步骤2)中,所述宿主细胞选用E.coli BL2。
6.如权利要求3所述重组piscidin 5-like type 4的制备方法,其特征在于在步骤3)中,先将步骤2)所得的表达产物进行透析,再进行亲和层析。
7.如权利要求3所述方法制备的rLc-p5L在制备抗虫药物中的应用。
8.如权利要求3所述方法制备的rLc-p5L在制备水产养殖业中防治病害的饲料添加剂中的应用。
CN202010512768.2A 2020-06-08 2020-06-08 大黄鱼抗菌肽piscidin 5-like type 4及其制备方法与应用 Active CN111574610B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202010512768.2A CN111574610B (zh) 2020-06-08 2020-06-08 大黄鱼抗菌肽piscidin 5-like type 4及其制备方法与应用

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202010512768.2A CN111574610B (zh) 2020-06-08 2020-06-08 大黄鱼抗菌肽piscidin 5-like type 4及其制备方法与应用

Publications (2)

Publication Number Publication Date
CN111574610A true CN111574610A (zh) 2020-08-25
CN111574610B CN111574610B (zh) 2023-05-02

Family

ID=72122248

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202010512768.2A Active CN111574610B (zh) 2020-06-08 2020-06-08 大黄鱼抗菌肽piscidin 5-like type 4及其制备方法与应用

Country Status (1)

Country Link
CN (1) CN111574610B (zh)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112266917A (zh) * 2020-10-15 2021-01-26 福建福鼎海鸥水产食品有限公司 大黄鱼抗肿瘤肽piscidin 5 like及其制备方法与应用
CN112280781A (zh) * 2020-10-15 2021-01-29 宁德市富发水产有限公司 大黄鱼抗菌肽piscidin 5 like type 4及其制备方法与应用
CN112501317A (zh) * 2020-12-28 2021-03-16 厦门大学 一组可应用于大黄鱼抗刺激隐核虫育种的snp标记

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101974082A (zh) * 2010-10-13 2011-02-16 厦门大学 一种大黄鱼hepcidin抗菌肽及其制备方法
CN102304536A (zh) * 2011-08-29 2012-01-04 厦门大学 两种海洋动物抗菌肽基因的真核融合表达产物及制备方法
CN106459163A (zh) * 2014-10-15 2017-02-22 深圳大学 马拉巴石斑鱼Piscidin的改造体抗菌肽及其应用
CN109295066A (zh) * 2018-10-26 2019-02-01 宁德市富发水产有限公司 大黄鱼抗菌肽piscidin 5 like及其制备方法与应用
CN109295065A (zh) * 2018-10-26 2019-02-01 宁德市富发水产有限公司 大黄鱼抗菌肽Hepcidin-like及其制备方法与应用

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101974082A (zh) * 2010-10-13 2011-02-16 厦门大学 一种大黄鱼hepcidin抗菌肽及其制备方法
CN102304536A (zh) * 2011-08-29 2012-01-04 厦门大学 两种海洋动物抗菌肽基因的真核融合表达产物及制备方法
CN106459163A (zh) * 2014-10-15 2017-02-22 深圳大学 马拉巴石斑鱼Piscidin的改造体抗菌肽及其应用
CN109295066A (zh) * 2018-10-26 2019-02-01 宁德市富发水产有限公司 大黄鱼抗菌肽piscidin 5 like及其制备方法与应用
CN109295065A (zh) * 2018-10-26 2019-02-01 宁德市富发水产有限公司 大黄鱼抗菌肽Hepcidin-like及其制备方法与应用

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
LIBING ZHENG: ""Excavating differentially expressed antimicrobial peptides from transcriptome of Larimichthys crocea liver in response to Cryptocaryon irritans"", 《FISH&SHELLFISH IMMUNOLOGY》 *
张毓霞等: "大弹涂鱼皮肤转录组测序及抗菌肽基因分析", 《生命科学研究》 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112266917A (zh) * 2020-10-15 2021-01-26 福建福鼎海鸥水产食品有限公司 大黄鱼抗肿瘤肽piscidin 5 like及其制备方法与应用
CN112280781A (zh) * 2020-10-15 2021-01-29 宁德市富发水产有限公司 大黄鱼抗菌肽piscidin 5 like type 4及其制备方法与应用
CN112501317A (zh) * 2020-12-28 2021-03-16 厦门大学 一组可应用于大黄鱼抗刺激隐核虫育种的snp标记
CN112501317B (zh) * 2020-12-28 2022-10-04 厦门大学 一组可应用于大黄鱼抗刺激隐核虫育种的snp标记

Also Published As

Publication number Publication date
CN111574610B (zh) 2023-05-02

Similar Documents

Publication Publication Date Title
CN111574610A (zh) 大黄鱼抗菌肽piscidin 5-like type 4及其制备方法与应用
JPH02502513A (ja) 病気抵抗体及び害虫抵抗体を植物に組み込む方法並びに植物に組み込まれ該抵抗体の暗号に対応する新規な遺伝子
CN110643612B (zh) 一种卵形鲳鲹抗菌肽NK-lysin基因及应用
CN110194790B (zh) 尖孢镰刀菌分泌的植物免疫激活蛋白FoPII1及其应用
CN111205359B (zh) 一种拟穴青蟹抗菌肽Scyreprocin及其应用
CN110922457B (zh) 禾谷镰刀菌分泌的植物免疫诱抗蛋白FgPII1及其应用
CN101173004A (zh) 一种昆虫抗菌肽Thanatin及其缺失突变体的制备方法
Zheng et al. Ferritin has an important immune function in the ark shell Scapharca broughtonii
CN110551732A (zh) 一种卵形鲳鲹抗菌肽leap-2基因及应用
CN101173005A (zh) 昆虫抗菌肽Thanatin衍生物及其制备方法与用途
CN113201059B (zh) 一种桃蛀螟活性抗菌肽及其基因、重组载体和应用
CN101525617A (zh) 中华绒螯蟹Crustin-1基因及体外重组表达
CN109295066A (zh) 大黄鱼抗菌肽piscidin 5 like及其制备方法与应用
CN109021088A (zh) 一种斑节对虾抗菌肽ALFpm10及其制备方法
RU2580031C2 (ru) ПЛАЗМИДНЫЙ ВЕКТОР pET-His8-TrxL-Acip1, ШТАММ БАКТЕРИИ Escherichia coli BL21(DE3)/pET-His8-TrxL-Acip1 ДЛЯ ЭКСПРЕССИИ АНТИМИКРОБНОГО ПЕПТИДА АЦИПЕНСИНА-1 И СПОСОБ ПОЛУЧЕНИЯ УКАЗАННОГО ПЕПТИДА
CN112375132B (zh) 太湖白鱼来源的抗菌肽及其应用
Sebastian et al. Molecular and Functional Characterization of an Anti-lipopolysaccharide Factor Mm-ALF from Speckled Shrimp Metapenaeus monoceros
Chaithanya et al. A novel isoform of the hepatic antimicrobial peptide, hepcidin (Hepc-CB1), from a deep-sea fish, the spinyjaw greeneye Chlorophthalmus bicornis (Norman, 1939): molecular characterisation and phylogeny
WO2021046401A1 (en) Systems, methods, and compositions for the inhibition of bacterial toxins to treat early mortality syndrome in aquatic animals
Zhou et al. The magnetic receptor of Monascus ruber M7: Gene clone and its heterologous expression in Escherichia coli
CN108218970B (zh) 一种重组蛋白及其制备方法和应用
CN111955486A (zh) 防治植物害虫的方法、核酸农药及其制备方法和应用
Sunil et al. In Silico Characterization of a Transcript Code Based Screening of Antimicrobial Peptide from Trichogramma chilonis
CN110128519B (zh) 一种重组荞麦防御素蛋白及其制备方法和应用
Guo et al. Characterization, functional analysis and antibacterial activities of theromacin from the Akoya pearl oyster Pinctada fucata

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant